Editorial on “Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy” by Marcucci et al.

• References

• 1 Marcucci R, Paniccia R, Antonucci E. et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy.. Thromb Haemost 2007; 98: 844-851.
• 2 Yusuf S, Zhao F, Mehta SR. et al.; Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.. N Engl J Med 2001; 345: 494-502.
• 3 Mehta SR, Yusuf S, Peters RJ. et al.; Clopidogrel in unstable angina to prevent recurrent events trial (CURE) investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.. Lancet 2001; 358: 527-533.
• 4 Geisler T, Gawaz M. Variable response to clopidogrel in patients with coronary artery disease.. Semin Thromb Hemost 2007; 33: 196-202.
• 5 Muller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.. Thromb Haemost 2003; 89: 783-787.
• 6 Cuisset T, Frere C, Quilici J. et al. High posttreatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.. J Thromb Haemost 2006; 4: 542-549.
• 7 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.. Eur Heart J 2006; 27: 2420-2425.
• 8 Hochholzer W, Trenk D, Bestehorn HP. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.. J Am Coll Cardiol 2006; 48: 1742-1750.
• 9 Geisler T, Kapp M, Göhring-Frischholz K. et al. Residual platelet activity is increased in Clopidogreland ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.. Heart 2007; epub ahead of print.
• 10 Chen WH, Lee PY, Ng W. et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.. J Am Coll Cardiol 2004; 43: 1122-1126.
• 11 Neumann FJ, Blasini R, Schmitt C. et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction.. Circulation 1998; 98: 2695-2701.
• 12 Neumann FJ, Hochholzer W, Pogatsa-Murray G. et al. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.. J Am Coll Cardiol 2001; 37: 1323-1328.
• 13 Boersma E, Harrington RA, Moliterno DJ. et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials.. Lancet 2002; 359: 189-198.
• 14 Ault KA, Cannon CP, Mitchell J. et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial.. J Am Coll Cardiol 1999; 33: 634-639.